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Using recombinant DNA techniques, we have made a series of amino-terminal muteins of human interleuk- 
in-l (IL-l). Two of the muteins demonstrated 4-7-fold increase in bioactivity as compared to that of the 
native IL-l. The enhanced biological potency coincides with an increase in both receptor binding affinity 
and in vivo tumor inhibitory activity. By site specific mutagenesis, we have shown that the arginine at the 
fourth position of IL-l is one of the key residues in the function of IL-l. Circular dichroism studies of the 
amino-terminus analogs showed little structural rearrangement. The change in bioactivity might be due to 
a change in the stability of the muteins, in the side chain interactions with receptors or in the minor change 
in folding near the receptor binding site. 
Interleukin-1; Site-directed mutagenesis; Antitumor agent 
1. INTRODUCTION 
Human interleukin-1 (IL-l) is a nonglycosylated 
cytokine, released by activated monocytes and 
macrophages, which mediates a diverse array of 
biological activities [l-3]. These activities include 
induction of thymocyte proliferation and B- 
lymphocyte differentiation, prostaglandin and col- 
lagenase release, induction of fever and possible 
involvement in cytotoxicity against certain tumor 
target cells [4-81. 
At present, there are at least two different forms 
of IL-l, designated a and fi, based on isoelectric 
point heterogeneity [9, lo]. Complementary DNA 
encoding IL-lcr and -fi have been cloned, se- 
quenced and expressed in Escherichia coli [lo- 161. 
The nucleic acid and amino acid sequence analyses 
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revealed that the homology between the two IL-l 
species is very limited, approx. 45 and 23070, 
respectively [lo]. The limited homology appears to 
be clustered within two structurally conserved do- 
mains, thought to be the potential active sites of 
IL-l [17]. It is striking that two distinct and 
distantly related molecules compete for the same 
receptor [18,19] and mediate the same spectrum of 
immunological and inflammatory responses [20]. 
It is therefore of interest to define specific residues 
which are involved in receptor binding and are im- 
portant for biological activities. 
Through the use of an expression system in E. 
coli large amounts of fully active recombinant IL-l 
(rIL-1) are now available for structural and func- 
tional characterization [ 13- 161. However there is a 
sparsity of information on the structure/function 
relationship of IL-l [21]. In a previous com- 
munication, we showed that the deletion of 
residues at the amino-terminus led to a total loss of 
biological activity of IL-l. This suggests that this 
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region of the molecules is essential for structure 
and/or function [ 161. These studies have prompted 
us to construct a series of N-terminal analogs of 
IL-l with which to further define the role of this 
region of the molecule. 
2. MATERIALS AND METHODS 
2.1. Bacterial strains and plasmids 
E. coli strain JMlOl, complementary DNA en- 
coding IL-l@ and the parental plasmid (pDP506A) 
used in this study are described in [ 11,161. Plasmid 
pDP506d was digested with EcoRI and Hind111 
and replaced with an oligomer (AATTCCATA- 
GAGGGTATTACATATGCTGGAGCATAGA- 
TCTCTGAACTGCACGCTCCGGGACTCACA- 
GCAAAAA) to generate the mature form of 
IL-lfl. The oligomer (73-mer), flanked by EcoRI 
and Hind111 restriction sites, includes a Shine 
Dalgarno (S/D) sequence (dotted line), transla- 
tional initiation codon, ATG (underlined), and a 
silent change at Argd-Sers coding sequence to 
generate a new restriction site BglII. A series of 
35mers (from EcoRI to BglII) was made, with 
proper coding sequence mutated, and used to 
generate various amino-terminal mutants. 
2.2. Purification and bioassay of mutein IL-I 
The rIL-1 was purified by a published procedure 
(161 and the biological activity was evaluated by 
the standard murine (C3H/HeJ) thymocyte pro- 
liferation assay [22]. rIL-l,& possessed specific ac- 
tivity comparable to that of native monocyte IL-l 
[9,13,16] as measured by fibroblast prostaglandin 
Ez production, thymocyte proliferation and EL4/9 
interleukin-2 production assays. 
2.3. Circular dichroism spectroscopy 
Muteins were kept in 20 mM phosphate buffer 
and 0.1 M NaCl at pH 7.0. The protein concentra- 
tions, 0.10 f 0.005 mg/ml, were determined by 
quantitative amino acid analysis. The spectra were 
acquired by averaging three repetitive scans on a 
Jobin-Yuon Mark V auto-dichrograph. 
2.4. Receptor binding assay 
IL-l was iodinated using the Bolton Hunter 
reagent and the binding of ‘251-IL-1 to EL 4/9 cells 
was carried out according to Dower et al. [ 181. 
2.5. Anti-tumor study 
Inhibition of B16 melanoma in vivo by recombi- 
nant IL-l was followed [23]. Briefly, C57BL/6 
mice (7 mice/clone tested) were transplanted i.d. 
with B16 melanoma cells (5 x lo5 cell/mouse) on 
day 0, rIL-1 was injected once a day on day 8 
through to 14 and inhibition rates were calculated 
on day 15. 
3. RESULTS AND DISCUSSION 
We took advantage of recombinant DNA 
technology to generate a series of N-terminal 
mutants with which to test the functional 
significance of IL-l’s amino-terminal sequence. 
The mutant plasmids were constructed, isolated, 
sequenced and expressed in E. co/i as described 
earlier [ 161. Recombinant protein from individual 
constructs was purified to homogeneity and its 
bioactivity evaluated [ 161. 
Table 1 shows the biologic activity of the 
analogs determined by the thymocyte proliferation 
assay [22]. Clone 22a, which had the substitution 
alanine to threonine at the amino-terminus of 
IL-l, showed a 4-fold increase in bioactivity. 
Another mutant (clone 18), in which the first two 
amino acids have been replaced, demonstrated 
7-fold enhanced activity. It has been shown that 
the flexibility and accessibility of the amino- 
terminus of a protein modulate its stability and 
function [24]. Bachmair et al. [25] speculated that 
the stability of a given protein is largely dependent 
on its amino-terminal residues. It is possible that 
the improved activity of these analogs is due to 
structural rearrangements that result in enhanced 
receptor binding. However, from circular 
dichroism (CD) measurements, no gross structural 
modification can be detected (fig.1). It is feasible 
that the modification of the amino-terminus can 
contribute to a more stable configuration or a 
minor change in structure which influences ac- 
tivity. 
The three-dimensional structure of a polypep- 
tide chain is determined by the total number of in- 
teratomic interactions and hence by the amino acid 
sequence. Examining the amino-end of the IL-l se- 
quence revealed that a protonated arginine (posi- 
tion 4 of IL-l@) might be involved in salt-bridge 
formation or hydrogen bonding which plays a role 
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Table 1 
Bioactivity of recombinant IL-l purified from amino-terminal mutants 
Clone Amino-terminus 
designation sequence of IL-l 
Spec. act.a 
(units/mg) 
Relative 
specificityb 
(Q) 
November 1987 
IL-l/3 Ala-Pro-Val-Arg-Ser-Leu- 1.0 + 0.0 x 10’ 100 
C-22a Thr-Pro-Val-Arg-Ser-Leu- 3.8 f 1.1 x 10’ 380 
C-18 Thr-Met-Val-Arg-Ser-Leu- 7.0 k 1.5 x 10’ 700 
Glu-4 Thr-Met-Val-Glu-Ser-Leu- 1.4 * 1.2 x lo4 0.14 
a One unit equals the amount of material which gives half of the maximum 
stimulation. Values are means f SE from 5 independent experiments and 
are normalized against IL-l,& (DP516) [16] 
b Calculated from spec. act. related to IL-lfl 
in stabilizing the protein structure. Substitution of 
arginine by glutamic acid (Glu-4), which is a single 
amino acid replacement compared to clone 18, 
resulted in a total loss of bioactivity. This sug- 
gested that the positively charged arginine residue 
is important in the structure and/or biological ac- 
tivity of IL-l. 
The receptor binding affinity of these mutants 
correlated well with the bioactivity (fig.2). Clone 
18 which showed enhanced activity, also 
demonstrates a higher receptor binding affinity to 
Fig. 1. Circular dichroism spectra of recombinant IL-l. 
Three recombinant proteins: IL-la (-), Clone-18 
(---) and Glu-4 (-----) were examined. 
the EL4/9 cells, a murine T-lymphoma cell line 
which responds to IL-l with IL-2 production [26]. 
The analog Glu-4 which exhibited an almost total 
loss of activity showed a low receptor binding af- 
finity as evidenced by the dramatic rightward shift 
in the competition assay (fig.2). Individual com- 
petition curves were paralleled suggesting that 
receptors are of a single class. Thus, the altered 
bioactivity of these analogs appears to result from 
changes in receptor binding rather than to post- 
receptor-mediated events. 
It has been shown that IL-l might be an effective 
antitumor agent against certain tumor targets 
[8,23,27]. It is interesting to note that the 
biological potency of IL-l as measured by an in 
vitro assay is reflected in in vivo antitumor activi- 
ty. Table 2 depicts the efficacy of different rIL-1 
muteins on a B16 melanoma tumor in C57BL/6 
mice [23]. The EDso, the dose that yields 50% in- 
hibition of tumor growth, corresponds well with 
the in vitro activity. Clone 18 has a lower EDso 
value indicative of its greater potency. Glu-4, 
however, showed no inhibition or toxicity at 
lOpg/mouse per day. 
All the recombinant clones described in this 
communication are produced in a similar fashion. 
The expression system and purification procedure 
of each clone are identical. Thus, it is possible that 
the variation in bioactivity is a result of the pro- 
tein’s secondary and tertiary structure. It is sur- 
prising that analyses of CD spectra reveal no 
detectable difference in the secondary structure of 
the various rIL-1s tested (fig.1). From a CD scan 
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Concontrrtlon of IL1 (M) 
Fig.2. The receptor binding assay of rZ51-labeled IL-l to EL4/9 cells. EL4/9 cells (2 x 10’ cells per ml) were incubated 
with ‘251-labeled IL-1 (0.2-l nM) and varying concentrations of unlabeled IL-l or IL-1 analogs IL-lfl (o), Clone-18 
(w) and Glu-4 (A) for 3 h at 37°C. 
of heat inactivated IL-l (not shown) a rearrange- 
ment in secondary structure indicative of increased 
P-sheet formation was observed. We concluded 
that the differences in activity of these recombi- 
nant proteins are not due to denaturation of the 
Table 2 
Anti-tumor effect of rIL-1 mutant proteins on B16 
melanoma 
Clone tested ED50a 
&g/mouse per day) 
IL-l,& 3.3 
Clone-18 1.8 
Glu-4 NEb 
a Dose response curves were generated for each 
recombinant protein by calculation of tumor mass [23] 
and the ED50 value was the dose that yielded 50% 
inhibition of tumor growth from two independent 
experiments 
b NE, not effective, Glu-4 gave no inhibition or toxicity 
at lOpg/mouse per day 
protein but, rather, are attributed by changes in 
folding of the polypeptides. 
In summary, we utilized site specific 
mutagenesis to engineer a series of recombinant 
IL-1s which have various degrees of bioactivity. 
Manipulation of the amino-terminal sequence of 
IL-l generated recombinant proteins that showed 
increased or decreased bioactivity as compared to 
native IL-l. Generally speaking, the terminal 
regions of proteins are less likely to be involved in 
the active center [24]; nevertheless, we have shown 
that the arginine at the amino-end of the IL-l 
molecule has a direct impact on configuration and 
bioactivity. The mutant clones described in this 
communication should prove of great value in ex- 
amining the structure-function relationship of IL-l 
and lead to the synthesis of agonists or antagonists 
for IL-l. 
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